# **BMJ Open** Analysis of multimorbidity networks associated with different factors in Northeast China: a crosssectional analysis

Jianxing Yu, Yingying Li, Zhou Zheng, Huanhuan Jia 💿 , Peng Cao, Yuzhen Qiangba, Xihe Yu 💿

# ABSTRACT

**Objectives** This study aimed to identify and study the associations and co-occurrence of multimorbidity, and assessed the associations of diseases with sex, age and hospitalisation duration.

Design Cross-sectional.

Setting 15 general hospitals in Jilin Province, China. Participants A total of 431 295 inpatients were enrolled through a cross-sectional study in Jilin Province. China. Primary outcome measures The complex relationships of multimorbidity were presented as weighted networks. Results The distributions of the numbers of diseases differed significantly by sex, age and hospitalisation duration (p<0.001). Cerebrovascular diseases (CD), hypertensive diseases (HyD), ischaemic heart diseases (IHD) and other forms of heart disease (OFHD) showed the highest weights in the multimorbidity networks. The connections between different sexes or hospitalisation duration and diseases were similar, while those between different age groups and diseases were different. Conclusions CD, HvD, IHD and OFHD were the central points of disease clusters and directly or indirectly related to other diseases or factors. Thus, effective interventions for these diseases should be adopted. Furthermore, different intervention strategies should be developed according to multimorbidity patterns in different age groups.

# **INTRODUCTION**

The term multimorbidity broadly refers to the presence of two or more health conditions (diseases) in a single individual.<sup>1–4</sup> With the continuing increase in life expectancy, multimorbidity has become a worldwide public health issue as it increases with age.<sup>5</sup> Additionally, multimorbidity is associated with increased adverse health outcomes such as poor quality of life, disability, hospitalisation, mortality and the concomitant use of healthcare resources and expenditure.<sup>6–9</sup> Furthermore, multimorbidity is also costly for both individuals and the healthcare system, with healthcare utilisation and costs increasing with each additional condition,<sup>10–12</sup>

# Strengths and limitations of this study

- This study visually demonstrated the differences in multimorbidity according to sex, age group and hospitalisation duration.
- Adjusting the analysis of multimorbidity patterns to the individual level rather than disease level could identify and study the associations and cooccurrence of multimorbidity.
- The model can be applied to assess the patterns of multimorbidity associated with different factors, and provide meaningful information for clinicians.
- The results were based on a cross-sectional study in Jilin Province, China, which might limit the generalisability of the results.

particularly in China, the world's most populous country.<sup>13 14</sup> Therefore, identifying the associations and co-occurrence of multimorbidity is an essential public health issue that requires urgent attention.

Most of the published literature on multimorbidity patterns focuses on disease level rather than individual level.<sup>1 10 15</sup> Adjusting the analysis of multimorbidity patterns to the individual level rather than disease level could identify and study the associations and co-occurrence of multimorbidity. Studying and treating diseases in isolation may not only lead to inefficiencies and duplication in the case of multimorbid patients but may also have serious implications if treatment for one disease contradicts that for another.<sup>1</sup> A multidimensional approach is required to understand the patterns of multimorbidity and recognise the associations between conditions within these patterns.

Furthermore, Aguado *et al*<sup>16</sup> pointed out that multimorbidity is a complex phenomenon that can be assessed using network analysis. Moreover, research on multiple disease networks has attracted increasing

**To cite:** Yu J, Li Y, Zheng Z, *et al.* Analysis of multimorbidity networks associated with different factors in Northeast China: a cross-sectional analysis. *BMJ Open* 2021;**11**:e051050. doi:10.1136/ bmjopen-2021-051050

Prepublication history for this paper is available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/bmjopen-2021-051050).

Received 13 March 2021 Accepted 18 October 2021

Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Social Medicine and Health Service Management, School of Public Health, Jilin University, Changchun, China

Correspondence to Dr Xihe Yu; xhyu@jlu.edu.cn attention in recent years. In their analysis of phenotyping networks, Hidalgo *et al*<sup>17</sup> reported that patients with highly connected diseases tended to die sooner. Glicksberg *et al*<sup>18</sup> observed race-specific disease networks based on a large-scale analysis of electronic medical records. In their multimorbidity network analyses, Kalgotra *et al* identified specific differences in disease diagnosis by sex and proposed questions for behavioural, clinical, biological and policy research; these researchers also identified specific differences in diagnoses among different population groups.<sup>19 20</sup>

However, these studies, while powerful and groundbreaking, did not adequately address the question of the associations of age, hospitalisation duration and diseases in their multimorbidity networks due to the limitations of their database. Thus, the present study aimed to identify and study the associations and co-occurrence of multimorbidity and provide meaningful information for clinicians. Another objective was to better understand the associations between common health conditions (diseases) to advance research into the mechanisms underpinning these common health conditions (diseases) associations. Finally, this study also assessed the associations of diseases with sex, age and hospitalisation duration.

# **METHODS**

## Study population

This study analysed data obtained from the hospital information systems or electronic medical record systems of 15 general hospitals in Jilin Province, China. The research objects were inpatients between 1 January 2018 and 31 December 2018, and the final study comprised 516 399 inpatients. For each included inpatient, the extracted variables were sex, age, hospitalisation duration, disease names and International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) classifications. To ensure the effectiveness and representativeness of the constructed disease network, the original medical data set was preprocessed to eliminate invalid patient records, including the following: (1) inpatients with some conditions or diseases such as injury, poisoning, certain infectious or parasitic diseases and congenital malformations; and (2) diseases occurring in fewer than 1000 inpatients (as the disease network was constructed without considering rare diseases). Finally, this study included 72 diseases to explore multimorbidity in 431 295 inpatients.

# **Data collection**

A multistage stratified random sampling method was used to obtain the sample data. First, through a comprehensive assessment of the geographical location, economic level and health service status of each city, Jilin, Changchun, Baicheng, Yanbian and Tonghua were finally included in the sample area, three general hospitals from each of these locations were then random selected. Finally, based on the administrative division, 15 general hospitals were selected as the monitoring institutions for this study. The inpatient data comprised continuous medical records, including indicators such as sex, age, hospitalisation duration, ICD-10 classification and disease name. To improve the data accuracy, we recruited and trained 20 people with proficiency in Excel software and medical backgrounds to form a professional team to check the accuracy of the basic information. Thirty general practitioners with more than 3 years of work experience confirmed that the names of the diseases matched the ICD-10 classifications.

## **Statistical analysis**

The categorical variables in this study were expressed as counts and percentages. Rao-Scott- $\chi^2$  tests were used to compare the distributions of the numbers of diseases and the complex relationships of multimorbidity were presented as weighted networks. The nodes represented diseases/factors, with the sizes of the nodes indicating their weight relative to all other diseases/factors. The edges represented the co-occurrence of a multimorbidity pair in the network, with the weight of the edge proportional to the prevalence of each pair. For inpatients with more than two diseases, the count of each multimorbidity pair would have an increment of 1 (eg, for an inpatient with ischaemic heart diseases (IHD), hypertensive disease (HyD) and cerebrovascular disease (CD), the multimorbidity pairs of IHD&HyD, IHD&CD and HyD&CD would increment by 1). The degree was defined as the number of nodes to which a focus node was connected, and was used to measure the node's participation in the network. The sparsity of the network was evaluated using the network density and average degree. The network density of an undirected graph with M edges and N nodes was defined as 2M/N(N-1), which described the proportion of potential connections (N(N-1)/2) in a network with actual connections (M). The larger the network density (or average degree), the denser the network.<sup>21-23</sup> The networks were analysed using the R package igraph. All statistical analyses were performed using RV.3.6.1 (R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/). Statistical significance was set at p<0.05.

#### Patient and public involvement

Patients were not involved in the study based on anonymised data.

## RESULTS

We analysed data from 431 295 inpatients in Jilin Province, China. As shown in table 1, the distributions of the numbers of diseases differed significantly by sex, age and hospitalisation duration (p<0.001). Additionally, the number of male inpatients was higher than that of female inpatients and the proportion of male inpatients with 2 or  $\geq$ 3 diseases was higher than that of female inpatients. Further, the proportion of inpatients with one disease

**Open** access

Table 1   Descriptive characteristics of the inpatients according to the number of diseases								
	n (%)	1	2	≥3	χ²	P value		
All inpatients	431 295 (100)	151 956 (35.23)	128 799 (29.86)	150 540 (34.9)				
Sex								
Male	216 248 (50.14)	71 712 (33.16)	67 498 (31.21)	77 038 (35.62)	856.93	<0.001		
Female	215 047 (49.86)	80 244 (37.31)	61 301 (28.51)	73 502 (34.18)				
Age (years)								
0–	37 081 (8.60)	25 165 (67.86)	8745 (23.58)	3171 (8.55)	30 981.20	<0.001		
18–	69 243 (16.05)	31 037 (44.82)	20 087 (29.01)	18 119 (26.17)				
45-	164 240 (38.08)	54 985 (33.48)	50 840 (30.95)	58 415 (35.57)				
65–	160 731 (37.27)	40 769 (25.36)	49 127 (30.56)	70 835 (44.07)				
Hospitalisation duration (days)								
0–	108 698 (25.20)	46 010 (42.33)	32 684 (30.07)	30 004 (27.60)	4809.34	<0.001		
5–	108 680 (25.20)	40 716 (37.46)	31 081 (28.60)	36 883 (33.94)				
8–	101 756 (23.59)	30 118 (29.60)	31 934 (31.38)	39 704 (39.02)				
12–	112 161 (26.01)	35 112 (31.30)	33 100 (29.51)	43 949 (39.18)				

decreased with age, while the proportion of inpatients with  $\geq 3$  diseases increased. Moreover, the results of hospitalisation duration were similar to those for the age groups and the proportion of inpatients with  $\geq 3$  diseases increased with increasing hospitalisation duration.

Table 2 shows the abbreviations and proportions of the 72 diseases. Among the 72 diseases, the maximum and minimum percentages were 19.34 and 0.30, respectively. Additionally, IHD, HyD, CD, other forms of heart disease (OFHD) and malignant neoplasms (MNE) had frequencies exceeding 50 000.

Figure 1 shows a visual representation of the network according to sex, age and hospitalisation duration. Both sexes had notably more connections in the 45–64 years and 65– years age groups; however, female inpatients had more connections for the 18–44 years age group compared with that in male inpatients. Additionally, the 45–64 years and 65– years age groups had notably more connections with the hospitalisation duration, with the 65– years age group showing more connections to 12– days hospitalisation duration. Finally, the connections between different sexes and hospitalisation duration were similar.

Figure 2 shows the multimorbidity network for 72 diseases. CD, HyD, IHD and OFHD had notably high weights (illustrated by the sizes of the nodes). In addition, the 'IHD-OFHD-HyD' triangle and 'CD-HyD' exhibited notably high connections in the multimorbidity networks (illustrated by the thicknesses of the lines connected to these nodes). Although MNE had notably high weights, no high connections to other diseases were observed compared with those for other high-weight diseases.

As illustrated in figure 3, the 'IHD-OFHD-Male', 'IHD-OFHD-Female', 'CD-HyD-Male' and 'CD-HyD-Female' triangles showed notably high connections in the networks. Moreover, CD and diabetes mellitus (DME)

had more notable connections with male inpatients compared with those in female inpatients.

Figure 4 shows the connections between different age groups and the 72 diseases. The older age group not only had more inpatients (illustrated by the sizes of the nodes) but also had more connections with other diseases (illustrated by the thicknesses of the lines connected to these nodes). Compared with other diseases, acute upper respiratory infections (AURI), influenza and pneumonia (IP) and OFHD had notably more connections with the <18 years age group. However, the 18–44 years age group had notably more connections to complications of labour and delivery (CLD), delivery (Del), maternal care related to the fetus and amniotic cavity and possible delivery problems (MCFAP), other maternal disorders predominantly related to pregnancy (OMDP) and metabolic disorders (MeD), and four of which were related to pregnancy and delivery. CD, HyD, IHD, OFHD and DME had notably more connections in the 45-64 years age group, and mainly cardiovascular and cerebrovascular diseases. In the 65- years age group, the 'CD-HyD-65-' and 'IHD-OFHD-65-' triangles showed the most network connections.

Figure 5 shows the networks for the different groups of hospitalisation duration and diseases. The weights were similar for the different groups of hospitalisation duration (illustrated by the node sizes). Moreover, CD, IHD, HyD, OFHD had more connections with the different groups of hospitalisation duration (illustrated by the thicknesses of the lines connected to these nodes).

# DISCUSSION

A major strength of this study was that it used a largescale, real-world clinical database of 431 295 inpatients in Jilin province, China. Additionally, the patterns of 

NoCode range code rangePresentage (%)1D60-D64Aplastic and other anaemiasAOA12.983.002M00-M25ArthropathiesArth89372.073J00-D66Acute upper respiratory infectionsAURI90142.094D10-D36Beingin neoplasmsBNE15.4623.595I60-067Complications of labour and deliveryCLD66171.586D80-D89Certain disorders involving the immune mechanismCIM12.990.307O60-O75Complications of labour and deliveryCLD66671.558J40-J47Chronic lower respiratory diseasesCLRD15.7723.669D65-D69Cacutation defects, purpura and other haemorrhagi conditionsCPH18190.4210G80-G83Cerebral palsy and other paralytic syndromesCPFS18190.4211170-179Diseases of arteries, atterioles and capillationDAC80613.7812H30-H36Disorders of chronid and retinaDAC40011.0713L20-L30Dermatitis and eczemaDE16750.3714O80-O84DeliveryDel16823.7815K80-K87Disorders of galbladder, biliay tract and panceaDAG64311.5216H25-H28Disorders of appendixDAG64531.5217E10-E14Diabetes mellitorsDAG65431.52 <th>Table 2</th> <th colspan="6">Abbreviations and proportions of the 72 diseases</th>	Table 2	Abbreviations and proportions of the 72 diseases					
1D60-D64Aplastic and other anaemiasAOA12 9383.002M00-M25ArthropathiesArth89372.073J00-J06Acute upper respiratory infectionsAURI90142.094D10-D36Benign neoplasmsBNE15 4623.595I60-I69Cerebrovascular diseasesCD68 14415.806D80-D89Certain disorders involving the immune mechanismCIM12990.307O60-O75Complications of labour and deliveryCLD66671.558J40-J47Chronic lower respiratory diseasesCLRD15 7723.669D65-D69Coagulation defects, purpura and other haemorrhagicCPH24320.5610G80-G83Cerebral palsy and other paralytic syndromesCPPS18190.4211170-179Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of gallbladder, pagesDME46 5101.7818N40-N51Diseases of mele genital organsDMGO65431.5219K35-K38Diseases of peritonumDOP23560.5521H40-K51Diseases of peritonumDOSD	No	ICD-10 code range	Disease name	Abbreviation	Frequency	Percentage (%)	
2   M00-M25   Arthropathies   Arth   8937   2.07     3   J00-J06   Acute upper respiratory infections   AURI   9014   2.09     4   D10-D36   Benign neoplasms   BNE   15 462   3.59     5   160-169   Cerction disorders involving the immune mechanism   CIM   1299   0.30     7   O60-O75   Complications of labour and delivery   CLD   6667   1.55     8   J40-J47   Chronic lower respiratory diseases   CLRD   15 772   3.66     9   D65-D69   Coreplication defects, purpura and other haemorrhagic   CPH   2432   0.56     10   G80-G83   Cerebral palsy and other paralytic syndromes   CPPS   1819   0.42     11   170-I79   Diseases of arteries, arterioles and capillaries   DAAC   8961   2.08     13   L20-L30   Dermatitis and eczema   DE   1755   0.37     14   O80-O84   Delivery   Del   1786   2.75     14   O80-K87   Diso	1	D60-D64	Aplastic and other anaemias	AOA	12 938	3.00	
3   J00-J06   Acute upper respiratory infections   AURI   9014   2.09     4   D10-D36   Benign neoplasms   BNE   15 462   3.59     5   160-I69   Cerebrovascular diseases   CD   68 144   15.80     6   D80-D89   Certain disorders involving the immune mechanism   CIM   1299   0.30     7   O60-075   Complications of labour and delivery   CLD   6667   1.55     8   J40-J47   Chronic lower respiratory diseases   CLRD   15 772   3.66     9   D65-D69   Coagulation defects, purpura and other haemorrhagic CPH   2432   0.56     10   G80-G83   Cerebral palsy and other paralytic syndromes   CPFS   1819   0.42     11   170-179   Diseases of arteries, arterioles and capillaries   DAAC   8961   2.08     12   H30-H36   Disorders of choroid and retina   DCR   4609   1.07     13   L20-L30   Dermatitis and eczema   DE   1757   0.37     14   O80-O84	2	M00-M25	Arthropathies	Arth	8937	2.07	
4 D10-D36 Benign neoplasms BNE 15 462 3.59   5 160-I69 Cerebrovascular diseases CD 68 144 15.80   6 D80-D89 Certain disorders involving the immune mechanism CIM 1299 0.30   7 O60-O75 Complications of labour and delivery CLD 6667 1.55   8 J40-J47 Chronic lower respiratory diseases CLPD 15 772 3.66   9 D65-D69 Coagulation defects, purpura and other haemorrhagic conditions CPH 2432 0.56   10 G80-G83 Cerebral palsy and other paralytic syndromes CPR 4609 1.07   11 I70-I79 Diseases of arteries, arterioles and capillaries DAAC 8961 2.08   12 H30-H36 Disorders of choroid and retina DCR 4609 1.07   13 L20-L30 Dermatitis and eczema DE 1575 0.37   14 O80-G84 Delivery Del 7782 1.80   15 K80-K87 Disorders of gallbladder, biliary tract and pancreas DIB 1654651 1.52 </td <td>3</td> <td>J00–J06</td> <td>Acute upper respiratory infections</td> <td>AURI</td> <td>9014</td> <td>2.09</td>	3	J00–J06	Acute upper respiratory infections	AURI	9014	2.09	
5I60-I69Cerebrovascular diseasesCD68 14415.806D80-D89Certain disorders involving the immune mechanismCIM12990.307O60-O75Complications of labour and deliveryCLD66671.558J40-J47Chronic lower respiratory diseasesCLRD15 7723.669D65-D69Coagulation defects, purpura and other haemornagic conditionsCPH24320.5610G80-G83Cerebral palsy and other paralytic syndromesCPS18190.4211170-I79Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDel77821.8014O80-O84DeliveryDel77821.8015K80-K87Disorders of lensDie11 8562.7516H25-H28Disorders of lensDie11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of appendixDOA48391.1220K70-K77Diseases of appendixDOA48391.2321K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of ovelopagus, stomach and duodenumDOSD21 1274.90 <t< td=""><td>4</td><td>D10-D36</td><td>Benign neoplasms</td><td>BNE</td><td>15 462</td><td>3.59</td></t<>	4	D10-D36	Benign neoplasms	BNE	15 462	3.59	
6D80-D89Certain disorders involving the immune mechanismCIM12990.307O60-O75Complications of labour and deliveryCLD66671.558J40-J47Chronic lower respiratory diseasesCLRD15 7723.669D65-D69Coagulation defects, purpura and other haemorrhagi conditionsCPH24320.5610G80-G83Cerebral palsy and other paralytic syndromesCPPS18190.4211170-179Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of alle genital organsDMGO65431.5217E10-E14Diseases of male genital organsDMGO65431.5218N40-N51Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of vierio, lymphatic vessels and lymphDVLL71911.6725E	5	160–169	Cerebrovascular diseases	CD	68 144	15.80	
7060-075Complications of labour and deliveryCLD66671.558J40-J47Chronic lower respiratory diseasesCLRD15 7723.669D65-D99Coagulation defects, purpura and other haemorrhagic conditionsCPH24320.5610G80-G83Cerebral palsy and other paralytic syndromesCPPS18190.4211170-179Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDME46 51010.7818N40-N51Diseases of appendixDMA48391.1220K70-K77Diseases of appendixDOA48391.1220K70-K77Diseases of appendixDOA48391.1220K70-K77Diseases of appendixDOA48391.1221K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of vins, lymphatic vessels and lymphDVLL<	6	D80–D89	Certain disorders involving the immune mechanism	CIM	1299	0.30	
8J40-J47Chronic lower respiratory diseasesCLRD15 7723.669D65-D69Coagulation defects, purpura and other haemorrhagic conditionsCPH24320.5610G80-G83Cerebral palsy and other paralytic syndromesCPS18190.4211170-179Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oral cavity, salivary glands and jawsDOS21 1274.9024K00-K14Diseases of vitrous body and globeDVBG13870.3225E00-E07Disorders of tyroid glandDTG75501.7526H43-H45Disorders of vitrous body and globeD	7	060–075	Complications of labour and delivery	CLD	6667	1.55	
9D65-D69 conditionsCoagulation defects, purpura and other haemorrhagic conditionsCPH24320.5610G80-G83Cerebral palsy and other paralytic syndromesCPPS18190.4211170-I79Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oceophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of vitreous body and globeDVBG13870.3225E00-E07Disorders of vitreous body and globeDVBG13870.3226H33-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins,	8	J40–J47	Chronic lower respiratory diseases	CLRD	15 772	3.66	
10G80-G83Cerebral palsy and other paralytic syndromesCPPS18190.4211I70-I79Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of leverDOL26 6636.1821K65-K67Diseases of peritoneumDOSD21 1274.9024K00-K14Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of vitreous body and globeDVBG13870.3225E00-E07Disorders of tyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Epsodic and parxysmal	9	D65-D69	Coagulation defects, purpura and other haemorrhagic conditions	CPH	2432	0.56	
11I70-I79Diseases of arteries, arterioles and capillariesDAAC89612.0812H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, billary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229Nu0-N08Glomerular diseases <td>10</td> <td>G80–G83</td> <td>Cerebral palsy and other paralytic syndromes</td> <td>CPPS</td> <td>1819</td> <td>0.42</td>	10	G80–G83	Cerebral palsy and other paralytic syndromes	CPPS	1819	0.42	
12H30-H36Disorders of choroid and retinaDCR46091.0713L20-L30Dermatitis and eczemaDE15750.3714O80-O84DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oral cavity, salivary glands and jawsDOSJ118030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	11	170–179	Diseases of arteries, arterioles and capillaries	DAAC	8961	2.08	
13 L20-L30 Dermatitis and eczema DE 1575 0.37   14 O80-O84 Delivery Del 7782 1.80   15 K80-K87 Disorders of gallbladder, biliary tract and pancreas DGBP 16 296 3.78   16 H25-H28 Disorders of lens Dle 11 856 2.75   17 E10-E14 Diabetes mellitus DME 46 510 10.78   18 N40-N51 Diseases of male genital organs DMGO 6543 1.52   19 K35-K38 Diseases of appendix DOA 4839 1.12   20 K70-K77 Diseases of peritoneum DOP 2356 0.55   21 K65-K67 Diseases of peritoneum DOP 2356 0.55   22 M40-M54 Dorsopathies Dors 10 131 2.35   23 K20-K31 Diseases of oesophagus, stomach and duodenum DOSD 21 127 4.90   24 K00-K14 Diseases of vitreous body and globe DVBG 1387 0.32   25 E00-E07 Disorders of vitreous body and globe </td <td>12</td> <td>H30–H36</td> <td>Disorders of choroid and retina</td> <td>DCR</td> <td>4609</td> <td>1.07</td>	12	H30–H36	Disorders of choroid and retina	DCR	4609	1.07	
14080-084DeliveryDel77821.8015K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and parxysmal disordersEPD15 6193.6229N00-N08Giomerular diseasesGD32340.75	13	L20-L30	Dermatitis and eczema	DE	1575	0.37	
15K80-K87Disorders of gallbladder, biliary tract and pancreasDGBP16 2963.7816H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of peritoneumDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oral cavity, salivary glands and jawsDOSJ21 1274.9024K00-K14Diseases of vitreous body and globeDVBG13870.3225E00-E07Disorders of tyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	14	080–084	Delivery	Del	7782	1.80	
16H25-H28Disorders of lensDle11 8562.7517E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of liverDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of vitreous body and globeDVBG13870.3227l80-l89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Giomerular diseasesGD32340.75	15	K80–K87	Disorders of gallbladder, biliary tract and pancreas	DGBP	16 296	3.78	
17E10-E14Diabetes mellitusDME46 51010.7818N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of liverDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of oesophagus, stordersEPD15 6193.6228G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	16	H25–H28	Disorders of lens	Dle	11 856	2.75	
18N40-N51Diseases of male genital organsDMGO65431.5219K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of liverDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	17	E10-E14	Diabetes mellitus	DME	46 510	10.78	
19K35-K38Diseases of appendixDOA48391.1220K70-K77Diseases of liverDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	18	N40-N51	Diseases of male genital organs	DMGO	6543	1.52	
20K70-K77Diseases of liverDOL26 6636.1821K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	19	K35–K38	Diseases of appendix	DOA	4839	1.12	
21K65-K67Diseases of peritoneumDOP23560.5522M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	20	K70–K77	Diseases of liver	DOL	26 663	6.18	
22M40-M54DorsopathiesDors10 1312.3523K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	21	K65–K67	Diseases of peritoneum	DOP	2356	0.55	
23K20-K31Diseases of oesophagus, stomach and duodenumDOSD21 1274.9024K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	22	M40-M54	Dorsopathies	Dors	10 131	2.35	
24K00-K14Diseases of oral cavity, salivary glands and jawsDOSJ18030.4225E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.75	23	K20-K31	Diseases of oesophagus, stomach and duodenum	DOSD	21 127	4.90	
25E00-E07Disorders of thyroid glandDTG75501.7526H43-H45Disorders of vitreous body and globeDVBG13870.3227I80-I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40-G47Episodic and paroxysmal disordersEPD15 6193.6229N00-N08Glomerular diseasesGD32340.7520H40, H42ClausamaClausamaClausama0.45	24	K00–K14	Diseases of oral cavity, salivary glands and jaws	DOSJ	1803	0.42	
26H43–H45Disorders of vitreous body and globeDVBG13870.3227I80–I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40–G47Episodic and paroxysmal disordersEPD15 6193.6229N00–N08Glomerular diseasesGD32340.7520H40, H42ClausamaClausamaClausama0.45	25	E00-E07	Disorders of thyroid gland	DTG	7550	1.75	
27I80–I89Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedDVLL71911.6728G40–G47Episodic and paroxysmal disordersEPD15 6193.6229N00–N08Glomerular diseasesGD32340.7520H40, H42ClausamaClausama0.45	26	H43–H45	Disorders of vitreous body and globe	DVBG	1387	0.32	
28   G40–G47   Episodic and paroxysmal disorders   EPD   15 619   3.62     29   N00–N08   Glomerular diseases   GD   3234   0.75     20   H40, H42   Clourearra   Clourearra   0.45	27	180–189	Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified	DVLL	7191	1.67	
29   N00–N08   Glomerular diseases   GD   3234   0.75     20   H40, H42   Cloures   Cloures   0.45	28	G40–G47	Episodic and paroxysmal disorders	EPD	15 619	3.62	
	29	N00-N08	Glomerular diseases	GD	3234	0.75	
30 H40-H42 Glaucollia Gla 1902 0.45	30	H40–H42	Glaucoma	Gla	1962	0.45	
31   K40–K46   Hernia   HI   3516   0.82	31	K40–K46	Hernia	HI	3516	0.82	
32   I10–I15   Hypertensive diseases   HyD   78 747   18.26	32	I10–I15	Hypertensive diseases	HyD	78 747	18.26	
33N70–N77Inflammatory diseases of female pelvic organsIDFP30140.70	33	N70-N77	Inflammatory diseases of female pelvic organs	IDFP	3014	0.70	
34   I20–I25   Ischaemic heart diseases   IHD   83 428   19.34	34	120–125	Ischaemic heart diseases	IHD	83 428	19.34	
35   J09–J18   Influenza and pneumonia   IP   37 290   8.65	35	J09–J18	Influenza and pneumonia	IP	37 290	8.65	
36L00-L08Infections of the skin and subcutaneous tissueISST24030.56	36	L00-L08	Infections of the skin and subcutaneous tissue	ISST	2403	0.56	
37J60–J70Lung diseases due to external agentsLDEA13280.31	37	J60–J70	Lung diseases due to external agents	LDEA	1328	0.31	
38O30-O48Maternal care related to the fetus and amniotic cavityMCFAP80411.86and possible delivery problems	38	O30–O48	Maternal care related to the fetus and amniotic cavity and possible delivery problems	MCFAP	8041	1.86	
39   E70–E90   Metabolic disorders   MeD   43 477   10.08	39	E70-E90	Metabolic disorders	MeD	43 477	10.08	
40 C00–C97 Malignant neoplasms MNE 56 980 13.21	40	C00–C97	Malignant neoplasms	MNE	56 980	13.21	
41   D50-D53   Nutritional anaemias   NAN   1722   0.40	41	D50-D53	Nutritional anaemias	NAN	1722	0.40	
42 N80–N98 Non-inflammatory disorders of female genital tract NDFG 10 227 2.37	42	N80-N98	Non-inflammatory disorders of female genital tract	NDFG	10 227	2.37	

Continued

Table 2	Continued				
No	ICD-10 code range	Disease name	Abbreviation	Frequency	Percentage (%)
43	K50-K52	Non-infective enteritis and colitis	NEC	13 421	3.11
44	G50–G59	Nerve, nerve root and plexus disorders	NPD	1964	0.46
45	F40–F48	Neurotic, stress-related and somatoform disorders	NSS	1532	0.36
46	D37–D48	Neoplasms of uncertain or unknown behaviour	NUB	3895	0.90
47	J20–J22	Other acute lower respiratory infections	OARI	7348	1.70
48	H49–H52	Disorders of ocular muscles, binocular movement, accommodation and refraction	OBAR	2967	0.69
49	D70–D77	Other diseases of blood and blood-forming organs	OBO	3116	0.72
50	M80-M94	Osteopathies and chondropathies	OC	5715	1.33
51	G30-G32	Other degenerative diseases of the nervous system	ODDNS	2133	0.49
52	K90–K93	Other diseases of the digestive system	ODDS	5737	1.33
53	K55–K63	Other diseases of intestines	ODI	17 525	4.06
54	N25-N29	Other disorders of kidney and ureter	ODKU	4442	1.03
55	G90–G99	Other disorders of the nervous system	ODNS	3302	0.77
56	J90–J94	Other diseases of pleura	ODP	5222	1.21
57	J95–J99	Other diseases of the respiratory system	ODRS	13 260	3.07
58	J30–J39	Other diseases of upper respiratory tract	ODRT	5612	1.30
59	N30-N39	Other diseases of urinary system	ODUS	9353	2.17
60	130–152	Other forms of heart disease	OFHD	67 632	15.68
61	020–029	Other maternal disorders predominantly related to pregnancy	OMDP	9398	2.18
62	094–099	Other obstetric conditions, not elsewhere classified	OOC	3138	0.73
63	010–016	Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium	OPHD	1390	0.32
64	J80–J84	Other respiratory diseases principally affecting the interstitium	ORDI	1922	0.45
65	000-008	Pregnancy with abortive outcome	PAO	2809	0.65
66	126–128	Pulmonary heart disease and diseases of pulmonary circulation	PHPC	2135	0.50
67	N17-N19	Renal failure	RF	11 562	2.68
68	N10-N16	Renal tubulo-interstitial diseases	RTD	2710	0.63
69	H15–H22	Disorders of sclera, cornea, iris and ciliary body	SCIC	1412	0.33
70	M30-M36	Systemic connective tissue disorders	SCTD	2149	0.50
71	M60-M79	Soft tissue disorders	STD	2204	0.51
72	N20-N23	Urolithiasis	Uro	3961	0.92

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision.

multimorbidity were based on the entire eligible sample. Another strength was that individual level rather than disease level was considered as the unit of analysis.<sup>15 24</sup> This approach permits a more rational and realistic monitoring of participants than cohort studies to analyse multimorbidity patterns over time.<sup>25</sup> In the syndemics theory proposed by Singer,<sup>26</sup> the effects of the presence of multiple diseases on a patient's health differ from their individual independent efffects. In other words, the risk of multimorbidity is greater than the sum of single

diseases. Furthermore, networks offer a more global picture because they include not only direct connections but also indirect associations, which provides more accurate information about multimorbidity. However, most current studies have compared different racial groups,<sup>17 18</sup> and few have evaluated the associations of disease patterns with sex, age and hospitalisation duration. The present study not only identified and studied the associations and co-occurrence of multimorbidity and provided meaningful information for clinicians but also



Figure 1 Network of sex, age and hospitalisation duration.

assessed the associations of diseases patterns with sex, age and hospitalisation duration.

Comparing the results of the present study to those by Hidalgo *et al*<sup>17</sup> on human phenotype using a dynamic network approach can be used to verify the reliability of the results of this study. Hidalgo *et al* found that many diseases were associated with HyD or IHD, consistent with the findings of the present study. Hidalgo *et al*<sup>17</sup> further demonstrated higher comorbidity for DME and HyD in black men compared with white men, and this study also confirmed more notable connections for DME in male inpatients compared with female inpatients.

Previous studies have shown that sex significantly affects multimorbidity.<sup>19 27 28</sup> In the present study, the proportion of multimorbidity was much higher in male inpatients than in female inpatients, a finding consistent with those of other studies.<sup>29–31</sup> Further, the disease associations in networks of both sexes revealed different disease associations according to sex. In the present study, 'CD-HyD' and 'IHD-OFHD' showed more connections



Figure 3 Multimorbidity networks with sex for 72 diseases.

with male inpatients and female inpatients, respectively. The connection between CD and HyD in both sexes has been well documented in the literature.<sup>32</sup> Additionally, CD and HyD share common risk factors such as obesity,<sup>33 34</sup> smoking and drinking.<sup>35</sup> Furthermore, CD and DME showed more connections with male inpatients than female inpatients, also consistent with the findings of other studies.<sup>17 36 37</sup>

Multimorbidity is often attributed to the ageing process, with a prevalence of approximately 62% in individuals aged 65-74 years and 81.5% in those older than 85 years of age.<sup>38</sup> A previous study showed an increasing tendency in the prevalence of multimorbidity in older adults.<sup>39 40</sup> The present study observed similar results, with more patients in the 65-74 years age group (table 1 and illustrated by the sizes of the nodes in figure 4). This may be due to higher body immunity and function in younger people compared with those in older people, thus, the proportion of diseases was lowest in the 0-17 years age group.

Furthermore, the main diseases differed across age groups; for instance, AURI and IP showed more connections in the <18 years age group. Other studies also found similar results.<sup>41–43</sup> Thus, more attention should be paid to respiratory system diseases in patients <18 years. Furthermore, CLD, Del, MCFAP, OMDP and MeD showed notably more connections in the 18–44 years age group.



Figure 2 Multimorbidity networks for 72 diseases.



Figure 4 Multimorbidity networks with age for 72 diseases.



**Figure 5** Multimorbidity networks with hospitalisation duration for 72 diseases.

This finding is likely related to the age at which women have children; and other studies have shown that women often develop metabolic disorders during pregnancy.<sup>44</sup> Thus, more attention should be given to female health. Moreover, the health challenges faced by the 45-64 years age group are more complex than those faced by other age groups because body immunity and function decline with age. Additionally, the population in this age group is under substantial mental stress, leading to feelings of exhaustion and illness. Therefore, multimorbidity studies individuals aged 45-64 years cannot be overlooked, particularly those on CD, HyD, IHD, OFHD and DME. Although this age group had a denser multimorbidity network, the 'CD-HyD-65-' and 'IHD-OFHD-65-' triangles showed more connections than those of other combinations. These findings suggest that different intervention strategies should be developed according to multimorbidity patterns in different age groups.

Finally, the results of this study showed that the stronger the disease connection to other diseases, the stronger the connection to the longer duration of hospitalisation. For example, HyD showed more marked connections with other diseases and a stronger connection with the group of patients with longer hospitalisation duration. Other studies have reported similar results. Specogna *et*  $al^{45}$  observed that patients with spontaneous intracerebral haemorrhage arriving at the hospital with HyD were 31% more likely to stay in the hospital beyond 1 week per visit compared with non-hypertensive patients.

This study had some limitations. First, the study participants were inpatients in Jilin Province, which could not represent the patterns of multimorbidity in other places. Second, this study investigated only sex, age and hospitalisation duration; however, other factors not considered in this study might have impacted multimorbidity. Finally, diseases occurring in fewer than 1000 inpatients were excluded, which might have caused bias.

## CONCLUSION

The results of this study visually demonstrated the differences in multimorbidity according to sex, age group and hospitalisation duration. Adjusting the analysis of multimorbidity patterns to the individual level revealed that IHD, HyD, CD and OFHD were the central points of disease clusters and were directly or indirectly related to other diseases and factors. Thus, accurate identification and effective intervention for these diseases should be adopted in the healthcare system. Furthermore, the government and relevant departments should develop different intervention strategies according to multimorbidity patterns in different age groups. Finally, the multimorbidity patterns were more consistent with clinical practice, allowing the effective management of patients with multimorbidity.

Acknowledgements We express our gratitude to the participants and colleagues who were involved in the study. We are also appreciative for the support of our funders

**Contributors** JY and XY had the original idea for the study and carried out the design. JY and XY provided valuable insight regarding the methodological approach and organization of the manuscript. JY, YL and ZZ carried out the statistical analysis and reviewed the consistency of data included in the paper. JY and YL drafted the manuscript. JY, HJ, PC and YQ revised the manuscript. All authors read and approved the final manuscript.

**Funding** This study is funding by the Ministry of Education (MOE) in China Project of Humanities and Social Sciences (Project No. 18YJAZH118).

#### Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the ethics committee of the School of Public Health, Jilin University (Reference Number: 2018-07-06).

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data may be obtained from a third party and are not publicly available. These data were from a survey conducted by the School of Public Health, Jilin University in Jilin Province in 2018. Because of relevant regulations, the data cannot be shared.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID iDs**

Huanhuan Jia http://orcid.org/0000-0003-4151-0915 Xihe Yu http://orcid.org/0000-0002-7076-1062

#### REFERENCES

- Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380:37–43.
- 2 Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic Condition—Multimorbidity. *JAMA* 2012;307:2493–4.
- 3 Ng SK, Tawiah R, Sawyer M, *et al.* Patterns of multimorbid health conditions: a systematic review of analytical methods and comparison analysis. *Int J Epidemiol* 2018;47:1687–704.
- 4 Van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature. The European Journal of General Practice 1996;2:65–70.
- 5 Salisbury C, Johnson L, Purdy S, et al. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011;61:e12–21.
- 6 Bähler C, Huber CA, Brüngger B, et al. Multimorbidity, health care utilization and costs in an elderly community-dwelling population:

# **Open access**

a claims data based observational study. *BMC Health Serv Res* 2015;15:23.

- 7 Bayliss EA, Ellis JL, Shoup JA, *et al*. Effect of continuity of care on hospital utilization for seniors with multiple medical conditions in an integrated health care system. *Ann Fam Med* 2015;13:123–9.
- 8 Rizzuto D, Melis RJF, Angleman S, *et al*. Effect of chronic diseases and multimorbidity on survival and functioning in elderly adults. *J Am Geriatr Soc* 2017;65:1056–60.
- 9 Garin N, Olaya B, Moneta MV, et al. Impact of multimorbidity on disability and quality of life in the Spanish older population. PLoS One 2014;9:e11149811.
- 10 Stairmand J, Gurney J, Stanley J. The impact of multimorbidity on people's lives: a cross-sectional survey. New Zealand Medical Journal 2018;131:78–90.
- 11 Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today's healthcare systems. *BMC Fam Pract* 2015;16:1.
- 12 Hu R-H, Hsiao F-Y, Chen L-J, et al. Increasing age- and genderspecific burden and complexity of multimorbidity in Taiwan, 2003-2013: a cross-sectional study based on nationwide claims data. BMJ Open 2019;9:e28333.
- 13 Wang SB, D'Arcy C, Yu YQ, et al. Prevalence and patterns of multimorbidity in northeastern China: a cross-sectional study. *Public Health* 2015;129:1539–46.
- 14 Wang HHX, Wang JJ, Wong SYS, et al. Epidemiology of multimorbidity in China and implications for the healthcare system: cross-sectional survey among 162,464 community household residents in southern China. BMC Med 2014;12:188.
- 15 Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, et al. Multimorbidity patterns: a systematic review. J Clin Epidemiol 2014;67:254–66.
- 16 Aguado A, Moratalla-Navarro F, López-Simarro F, et al. MorbiNet: multimorbidity networks in adult general population. Analysis of type 2 diabetes mellitus comorbidity. Sci Rep 2020;10:2416.
- 17 Hidalgo CA, Blumm N, Barabási A-L, et al. A dynamic network approach for the study of human phenotypes. *PLoS Comput Biol* 2009;5:e1000353.
- 18 Glicksberg BS, Li L, Badgeley MA, *et al.* Comparative analyses of population-scale phenomic data in electronic medical records reveal race-specific disease networks. *Bioinformatics* 2016;32:i101–10.
- 19 Kalgotra P, Sharda R, Croff JM. Examining health disparities by gender: a multimorbidity network analysis of electronic medical record. Int J Med Inform 2017;108:22–8.
- 20 Kalgotra P, Sharda R, Croff JM. Examining multimorbidity differences across racial groups: a network analysis of electronic medical records. *Sci Rep* 2020;10:13538.
- 21 Harding A. Actor-Network-Theory and Micro-Learning networks. Educ Prim Care 2017;28:295–6.
- 22 Tang C-L, Wang W-X, Wu X, et al. Effects of average degree on cooperation in networked evolutionary game. Eur Phys J B 2006;53:411–5.
- 23 Jin L, Guo X, Dou J, et al. Multimorbidity analysis according to sex and age towards cardiovascular diseases of adults in northeast China. Sci Rep 2018;8:8607.
- 24 Violán C, Roso-Llorach A, Foguet-Boreu Q, et al. Multimorbidity patterns with k-means nonhierarchical cluster analysis. BMC Fam Pract 2018;19:108.
- 25 Violán C, Foguet-Boreu Q, Fernández-Bertolín S, et al. Soft clustering using real-world data for the identification of multimorbidity patterns in an elderly population: cross-sectional study in a Mediterranean population. BMJ Open 2019;9:e029594.
- 26 Singer M. A dose of drugs, a touch of violence, a case of AIDS: Conceptualizing the SAVA syndemic. *Free Inquiry in Creative Sociology* 2000;28:13–24.

- 27 Schäfer I, von Leitner E-C, Schön G, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. *PLoS One* 2010;5:e1594112.
- 28 Schäfer I, Kaduszkiewicz H, Wagner H-O, et al. Reducing complexity: a visualisation of multimorbidity by combining disease clusters and triads. BMC Public Health 2014;14:1285.
- 29 Yu J, Song F, Li Y, et al. Multimorbidity analysis of 13 systemic diseases in northeast China. Int J Environ Res Public Health 2020;17:18176.
- 30 Muga MA, Owili PO, Hsu C-Y, *et al.* Association between dietary patterns and cardiovascular risk factors among middle-aged and elderly adults in Taiwan: a population-based study from 2003 to 2012. *PLoS One* 2016;11:e157745.
- 31 Yu J, Tao Y, Dou J, *et al*. The dose-response analysis between BMI and common chronic diseases in northeast China. *Sci Rep* 2018;8:4228.
- 32 He D, Yu Y, Wu S, et al. Mixed cerebrovascular disease in an elderly patient with mixed vascular risk factors: a case report. BMC Neurol 2019;19:11.
- 33 Pollack LM, Wang M, Leung MYM, et al. Obesity-Related multimorbidity and risk of cardiovascular disease in the middle-aged population in the United States. *Prev Med* 2020;139:106225.
- 34 Taylor LE, Sullivan JC. Sex differences in obesity-induced hypertension and vascular dysfunction: a protective role for estrogen in adipose tissue inflammation? *Am J Physiol Regul Integr Comp Physiol* 2016;311:R714–20.
- 35 Shiue I. Self and environmental exposures to drinking, smoking, gambling or video game addiction are associated with adult hypertension, heart and cerebrovascular diseases, allergy, self-rated health and happiness: Japanese General social survey, 2010. Int J Cardiol 2015;181:403–12.
- 36 Polsky S, Akturk HK. Alcohol consumption, diabetes risk, and cardiovascular disease within diabetes. *Curr Diab Rep* 2017;17:13612.
- 37 Yu J, Ma Y, Yang S. Risk factors for cardiovascular disease and their clustering among adults in Jilin (China). Int J Environ Res Public Health 2015;131:h13010070.
- 38 Salive ME. Multimorbidity in older adults. *Epidemiol Rev* 2013;35:75–83.
- 39 Ishizaki T, Kobayashi E, Fukaya T, et al. Association of physical performance and self-rated health with multimorbidity among older adults: results from a nationwide survey in Japan. Arch Gerontol Geriatr 2019;84:103904.
- 40 Zemedikun DT, Gray LJ, Khunti K, et al. Patterns of multimorbidity in middle-aged and older adults: an analysis of the UK Biobank data. Mayo Clin Proc 2018;93:857–66.
- 41 Teng B, Zhang X, Yi C, et al. The association between ambient air pollution and allergic rhinitis: further epidemiological evidence from Changchun, northeastern China. Int J Environ Res Public Health 2017;14:226.
- 42 Zheng P-W, Wang J-B, Zhang Z-Y, et al. Air pollution and hospital visits for acute upper and lower respiratory infections among children in Ningbo, China: a time-series analysis. *Environ Sci Pollut Res Int* 2017;24:18860–9.
- 43 Yu H, Huang J, Huai Y, et al. The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012. *Influenza Other Respir Viruses* 2014;8:53–65.
- 44 Patti AM, Pafili K, Papanas N, et al. Metabolic disorders during pregnancy and postpartum cardiometabolic risk. Endocr Connect 2018;7:E1–4.
- 45 Specogna AV, Turin TC, Patten SB, *et al*. Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke. *BMC Neurol* 2017;17:158.